Carbohydrate modification of proteins and lipids is the functional fine-tuning of these molecules. It is not surprising, therefore, that errors in glycosylation have severe implications and are found associated with common diseases such as cancer and diabetes. Carbohydrates have historically been desirable targets for drug intervention, but success stories have been limited. Recent advances in synthetic and analytical methods are facilitating a better understanding of the role of glycoproteins and carbohydrates in many cellular and signaling processes, and paving the way for carbohydrate drug discovery. This conference will showcase many of the technical advances in glycobiology and carbohydrate chemistry that have been made recently, along with several case studies of applications in drug development, ranging from carbohydrate-based compounds to modifications of recombinant biomolecules for drug delivery.

SCIENTIFIC ADVISORS
Dr. Tillman Gerngross, GlycoFi, Inc.
Dr. Yoshi Ichikawa, Optimer Pharmaceuticals, Inc.
Dr. Craig Karr, Tecan
Dr. Nicolle Packer, Proteome Systems Ltd.
Dr. Vern Reinhold, University of New Hampshire
Dr. Peter H. Seeberger, ETH Hönggerberg
Dr. Ashok K. Shukla, Glygen Corporation

SPEAKERS
Dr. Joseph J. Barchi, Jr., National Cancer Institute
Dr. Ten Feizi, The Glycosciences Laboratory, Imperial College
Dr. Tillman Gerngross, GlycoFi, Inc.
Dr. Johanna Griffin, Procognia, Inc.
Ms. Ann Grow, VP & CTO, Biopraxis, Inc.
Dr. Andrew Hanneman, University of New Hampshire
Dr. Sarah Harcum, Clemson University
Dr. Christoph Joosten, Bristol-Myers Squibb
Mr. Craig Karr, Tecan
Dr. Ravi Kumar, Scientist, Wyeth Pharmaceuticals
Dr. Steven B. Levery, University of New Hampshire
Dr. Werner Meier, Biogen, Inc.
Dr. Fred E. Regnier, Purdue University
Dr. Vernon Reinhold, University of New Hampshire
Dr. Kate Rittenhouse-Olson, SUNY-Buffalo
Dr. Peter Seeberger, ETH Hönggerberg
Dr. Joseph Siemiatkoski, Biogen Idec
Dr. Angus Sinclair, Amgen, Inc.
Prof. Reinhard Vlasak, Institute of Molecular Biology
Dr. John N. Vournakis, Marine Polymer Technologies, Inc.
Dr. Sheng Zhang, Advion BioSciences, Inc.

ANALYSIS
Sequential Mass Spectrometry Reveals Abundant Unusual N-Glycans in C. elegans
Recombinant Viral Esterases as Tools to Study the Functions of Oacetylated Sialic Acids
µSERST-Rapid Profiling of Carbohydrates and Their Interactions
Quantitative, Automated Glycoanalysis with U-C Fingerprint Technology
Developing and Applying Quantitative Methods for Recognizing
Disease-Related Variations in Protein Glycosylation

GLYCOSYLATION OF RECOMBINANT PROTEINS
Glycosylation Engineering of Recombinant Proteins for Structural Studies
Glycoproteins Produced in Genetically Engineered Yeast: A New Discovery and Manufacturing Paradigm
Gene Expression Analysis of Glycosylation Pathway Enzymes for Galactose-Fed CHO Cells
Sialylated Glycoprotein Production in Insect Cells
 

GLYCOMICS IN DRUG DISCOVERY AND DEVELOPMENT
Automated Synthesis and Carbohydrate Arrays
The Use of Carbohydrate Microarrays in Drug Discovery Related to De-Orphaning Glycomics-Derived Targets
Carbohydrate Microarrays for Assignments of the Ligands of Carbohydrate-Binding Proteins of the Immune System
Carbohydrates: Eliciting and Analyzing the Immune Response
Chip-Based Electrospray Ion Trap MSn Mass Spectrometry for the
Characterization of Protein Glycosylation: Application for Drug
Discovery and Biomedical Research
O-linked Glycosylation, Site Specificity and Quantification

THERAPEUTICS
Polysaccharide-Based Cancer Vaccine
Glycoengineering for Enhancing In Vivo Therapeutic Protein Activity
Sugar-Coated Nanoparticles: Novel Scaffolds for the Study of Glycan and Glycopeptide-Mediated Processes
Glycosphingolipids as Potential Targets for Antifungal Therapeutics and Diagnostics
Title to Be Determined